One case involved a female, age 42, with a history of bipolar I disorder, post-traumatic stress disorder (PTSD), morbid ...

A novel combination of two cancer drugs has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML), one of the most common types of blood cancers. A new study has ...

The global GLP-1 receptor agonist market is poised for remarkable expansion in the coming decade, according to a recent market analysis. Projections suggest an impressive surge from US$ 23,854.53 ...

With its newly launched predictive analytics platform, Real Chemistry is hoping to “shine a light” on the GLP-1 agonist ...

Palatin Technologies (PTN) stock gains as the FDA clears a study to test its obesity therapy bremelanotide, with Eli Lillys ...

Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid ...

With the FDA greenlighting its investigational new drug (IND) application, the company is eyeing a mid-2024 timeline to begin ...

"The conclusion of enrollment for Regimen G marks a critical step forward for the HEALEY ALS platform Trial," said Drs. Paganoni and Babu. "We extend our thanks to Denali, academic collaborators, and ...

There are more than 50 glucagon-like peptide-1 receptor agonists (GLP-1RAs) in clinical development for Type 2 diabetes, ...

DD01 is a long-acting dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors. The designation was based on data from a randomized, double-blind, placebo-controlled phase 1 study ...

ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) ...